Selecta Biosciences, Inc. Receives $3 Million from National Institutes of Health (NIH)/National Institute on Drug Abuse (NIDA) to Develop Nicotine Vaccine for Smoking Cessation

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, today announced that it has been awarded a grant for $3 million from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH). The grant is aimed at advancing the development of an enhanced therapeutic nicotine vaccine for the treatment of smoking cessation and relapse prevention.

Back to news